Cerus stock
CERSNASDAQCerus Corporation, HealthcareISIN US1570851014
33Score 33 out of 100, Weak
Price and trend
31 / 100
Price history
+18% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 20% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 36).
The price is 41% below its 52-week high. Largest decline in 20 years: 94% (October 2007 to December 2008).
Chart figures for advanced users
- SMA 50$2.37
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.43
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)36
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.49
- The lowest closing price of the last twelve months.
- Resistance$3.28
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Cerus Corporation belongs to the Medical (Devices) industry (United States) and, with a market value of $391.79M, is number 85 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $206.13M (up 14.3% year on year) and a loss of $15.63M.
- For fiscal 2026, analysts expect on average revenue of $255M (up 23.7%) and adjusted earnings per share of −$0.03.
Show more
- MEQIRI Score 33 out of 100 (Weak): rank 640 of 702 in Healthcare, median 53.
- Our model puts fair value at $0.51, with the price 281% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Above fair valuePrice 281% above the fair value of $0.51.Valuation 18
- Loss-makingLoss of $7.31M over the last 12 months.Fundamentals 17
- Volatile share priceVolatility 75% a year over the last 12 months.Stability 40
The score is held back by capital allocation and fundamentals.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 36 to 33.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $0.34 and expensive above $1.02 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9%. At 10% the fair value would be $0.46, at 8% it would be $0.58.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 13.7% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 54%, operating −4%, net −8%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 108 days
- Last reported
- 2 Nov 2026EPS reported $0.00 (expected −$0.01)above expectations
Analyst estimates
- Earnings per share
- −$0.03+38.9%
- Revenue
- $255M0.0%
- Earnings per share
- −$0.01+20.0%
- Revenue
- $277.05M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −25.1%2026 product revenue guidance raised to $229 million to $231 million (from $227 million to $231 million), IFC revenue to $23 million to $25 million (from $22 million to $24 million).
“As a result, we are raising the low end of our full year 2026 product revenue guidance range and now expect product sales of $229 to $231 million compared to our previous range of $227 to $231 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $840,674 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Jensen ChrystalSale
17 Aug 2026, Chief Legal Officer
- Shares
- 30,000
- Price
- $2.98
- Value
- $89,529
- Jayaraman Vivek KSale
16 Jul 2026, Chief Executive Officer
- Shares
- 16,666
- Price
- $3.16
- Value
- $52,665
- Green Kevin DennisSale
30 Jun 2026, Chief Financial Officer
- Shares
- 33,676
- Price
- $2.94
- Value
- $99,105
Show 5 more
- Jayaraman Vivek KSale
30 Jun 2026, Chief Operating Officer
- Shares
- 42,359
- Price
- $2.94
- Value
- $124,658
- Jensen ChrystalSale
30 Jun 2026, Chief Legal Officer
- Shares
- 24,329
- Price
- $2.94
- Value
- $71,598
- Greenman William MarinerSale
30 Jun 2026, President and CEO
- Shares
- 101,919
- Price
- $2.94
- Value
- $299,937
- Bjerkholt EricSale
9 Jun 2026, Board
- Shares
- 20,454
- Price
- $2.60
- Value
- $53,180
- Jayaraman Vivek KSale
29 May 2026, Chief Operating Officer
- Shares
- 16,667
- Price
- $3.00
- Value
- $50,001
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Cerus
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 33
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- CellaVisionCEVI.ST $483.11M80
- Metall ZugMETN.SW $460.29M40
- Revenio GroupREG1V.HE $419.17M47
- NeuroPaceNPCE $412.58M32
- ImplanticaIMP-A-SDB.ST $400.4M50
- StratecSBS.DE $360.32M52
- Treace Medical ConceptsTMCI $350.09M48
- CapsoVisionCV $333.63M38
ETFs that hold Cerus
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.22B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.28B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2013)
- Valuation signal Overvalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.